| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 30 | 2026 | 1841 | 2.680 |
Why?
|
| Breast Neoplasms | 53 | 2026 | 3279 | 2.230 |
Why?
|
| Randomized Controlled Trials as Topic | 28 | 2026 | 992 | 2.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 20 | 2026 | 160 | 2.100 |
Why?
|
| Androgen Antagonists | 14 | 2026 | 157 | 2.080 |
Why?
|
| Research Design | 12 | 2025 | 650 | 2.050 |
Why?
|
| Neoplasm Recurrence, Local | 25 | 2026 | 1539 | 1.730 |
Why?
|
| Tamoxifen | 21 | 2026 | 176 | 1.480 |
Why?
|
| Brain Neoplasms | 9 | 2025 | 843 | 1.250 |
Why?
|
| Glioblastoma | 6 | 2025 | 300 | 1.220 |
Why?
|
| Proportional Hazards Models | 21 | 2024 | 921 | 1.160 |
Why?
|
| Data Interpretation, Statistical | 9 | 2024 | 311 | 1.110 |
Why?
|
| Neoplasms | 17 | 2025 | 3348 | 1.100 |
Why?
|
| Clinical Trials as Topic | 14 | 2025 | 1126 | 0.990 |
Why?
|
| Prostate-Specific Antigen | 12 | 2026 | 356 | 0.970 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2016 | 171 | 0.890 |
Why?
|
| Statistics as Topic | 2 | 2021 | 229 | 0.880 |
Why?
|
| Models, Statistical | 7 | 2025 | 602 | 0.860 |
Why?
|
| Survival Analysis | 21 | 2024 | 1528 | 0.770 |
Why?
|
| Disease-Free Survival | 30 | 2025 | 1194 | 0.760 |
Why?
|
| Humans | 133 | 2026 | 98223 | 0.710 |
Why?
|
| Obesity | 6 | 2021 | 1076 | 0.680 |
Why?
|
| Receptors, Estrogen | 17 | 2012 | 430 | 0.670 |
Why?
|
| Antineoplastic Agents | 13 | 2021 | 2379 | 0.640 |
Why?
|
| Biomarkers, Tumor | 11 | 2019 | 1770 | 0.630 |
Why?
|
| Aged | 63 | 2026 | 21824 | 0.610 |
Why?
|
| Middle Aged | 77 | 2026 | 29494 | 0.590 |
Why?
|
| Biomarkers | 4 | 2025 | 2020 | 0.590 |
Why?
|
| Biometry | 4 | 2025 | 70 | 0.530 |
Why?
|
| Male | 56 | 2026 | 47195 | 0.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2025 | 2660 | 0.490 |
Why?
|
| Medical Futility | 1 | 2016 | 34 | 0.480 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2026 | 134 | 0.470 |
Why?
|
| Prognosis | 25 | 2024 | 4126 | 0.470 |
Why?
|
| Chemotherapy, Adjuvant | 14 | 2011 | 525 | 0.460 |
Why?
|
| Female | 76 | 2026 | 51685 | 0.460 |
Why?
|
| Risk Assessment | 14 | 2024 | 2598 | 0.450 |
Why?
|
| Salvage Therapy | 3 | 2024 | 240 | 0.450 |
Why?
|
| Mastectomy, Segmental | 9 | 2026 | 115 | 0.450 |
Why?
|
| Colonic Neoplasms | 6 | 2016 | 584 | 0.440 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2015 | 154 | 0.430 |
Why?
|
| Prostatectomy | 6 | 2026 | 491 | 0.430 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 265 | 0.410 |
Why?
|
| Radiation Oncology | 2 | 2016 | 130 | 0.400 |
Why?
|
| Odds Ratio | 11 | 2020 | 726 | 0.390 |
Why?
|
| Neoplasm Staging | 19 | 2018 | 2085 | 0.390 |
Why?
|
| Disease Progression | 10 | 2020 | 1612 | 0.390 |
Why?
|
| Treatment Outcome | 24 | 2024 | 9750 | 0.380 |
Why?
|
| Likelihood Functions | 3 | 2014 | 258 | 0.360 |
Why?
|
| Body Mass Index | 5 | 2013 | 867 | 0.360 |
Why?
|
| Clinical Trials Data Monitoring Committees | 2 | 2016 | 3 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2018 | 906 | 0.350 |
Why?
|
| Medical Oncology | 3 | 2024 | 423 | 0.350 |
Why?
|
| Time Factors | 16 | 2025 | 5573 | 0.350 |
Why?
|
| Lymph Nodes | 4 | 2012 | 560 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1946 | 0.330 |
Why?
|
| Survival Rate | 17 | 2017 | 2050 | 0.330 |
Why?
|
| Aged, 80 and over | 21 | 2025 | 7409 | 0.320 |
Why?
|
| Follow-Up Studies | 17 | 2024 | 4041 | 0.310 |
Why?
|
| Neoplasms, Second Primary | 5 | 2006 | 244 | 0.310 |
Why?
|
| Patient Compliance | 1 | 2011 | 245 | 0.300 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 508 | 0.290 |
Why?
|
| Cognition Disorders | 1 | 2011 | 239 | 0.290 |
Why?
|
| Estrogen Antagonists | 5 | 2004 | 47 | 0.290 |
Why?
|
| Lymphatic Metastasis | 11 | 2012 | 520 | 0.290 |
Why?
|
| Adult | 35 | 2025 | 29548 | 0.280 |
Why?
|
| Combined Modality Therapy | 14 | 2026 | 1751 | 0.280 |
Why?
|
| Risk Factors | 16 | 2024 | 6269 | 0.270 |
Why?
|
| Multicenter Studies as Topic | 6 | 2012 | 195 | 0.270 |
Why?
|
| Health Status Disparities | 2 | 2011 | 243 | 0.260 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 336 | 0.260 |
Why?
|
| DNA Modification Methylases | 2 | 2025 | 36 | 0.250 |
Why?
|
| DNA Repair Enzymes | 2 | 2025 | 65 | 0.250 |
Why?
|
| United States | 19 | 2025 | 8252 | 0.240 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2018 | 152 | 0.240 |
Why?
|
| Neoplasm Grading | 8 | 2024 | 425 | 0.240 |
Why?
|
| Pleural Neoplasms | 3 | 2013 | 207 | 0.240 |
Why?
|
| Margins of Excision | 1 | 2026 | 51 | 0.240 |
Why?
|
| Quality of Life | 6 | 2025 | 1897 | 0.240 |
Why?
|
| Mesothelioma | 4 | 2013 | 346 | 0.230 |
Why?
|
| Cause of Death | 3 | 2019 | 278 | 0.230 |
Why?
|
| Genes, BRCA1 | 4 | 2008 | 191 | 0.220 |
Why?
|
| Health Services Accessibility | 4 | 2021 | 533 | 0.220 |
Why?
|
| Drug Administration Schedule | 5 | 2018 | 836 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2025 | 314 | 0.220 |
Why?
|
| Radiotherapy Dosage | 4 | 2025 | 479 | 0.210 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2003 | 10 | 0.210 |
Why?
|
| Endpoint Determination | 3 | 2020 | 65 | 0.210 |
Why?
|
| Tosyl Compounds | 3 | 2021 | 14 | 0.200 |
Why?
|
| Incidence | 6 | 2022 | 1786 | 0.200 |
Why?
|
| Double-Blind Method | 10 | 2026 | 1787 | 0.200 |
Why?
|
| Radiotherapy | 6 | 2017 | 325 | 0.190 |
Why?
|
| Anilides | 3 | 2021 | 50 | 0.190 |
Why?
|
| Nitriles | 3 | 2021 | 171 | 0.180 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 23 | 0.180 |
Why?
|
| Dacarbazine | 4 | 2017 | 104 | 0.180 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2002 | 166 | 0.180 |
Why?
|
| Mass Screening | 4 | 2019 | 750 | 0.180 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 1090 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2003 | 138 | 0.170 |
Why?
|
| Immunotherapy | 2 | 2024 | 826 | 0.170 |
Why?
|
| Social Class | 2 | 2016 | 156 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2017 | 136 | 0.160 |
Why?
|
| Electronic Mail | 1 | 2020 | 17 | 0.160 |
Why?
|
| Pneumonia | 1 | 2022 | 195 | 0.160 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 2467 | 0.160 |
Why?
|
| Coronavirus | 1 | 2020 | 21 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2012 | 168 | 0.160 |
Why?
|
| Kallikreins | 1 | 2020 | 47 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2022 | 166 | 0.160 |
Why?
|
| Treatment Failure | 4 | 2017 | 300 | 0.150 |
Why?
|
| Patient Readmission | 1 | 2024 | 426 | 0.150 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2024 | 329 | 0.150 |
Why?
|
| Confidence Intervals | 2 | 2014 | 221 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 4 | 2011 | 1088 | 0.150 |
Why?
|
| Longitudinal Studies | 3 | 2025 | 1295 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2018 | 1107 | 0.150 |
Why?
|
| Risk | 5 | 2019 | 660 | 0.150 |
Why?
|
| Educational Status | 3 | 2020 | 205 | 0.140 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2019 | 36 | 0.140 |
Why?
|
| Breast | 3 | 2013 | 315 | 0.140 |
Why?
|
| Cisplatin | 2 | 2018 | 578 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2004 | 471 | 0.140 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 59 | 0.140 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 33 | 0.140 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2025 | 200 | 0.140 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 52 | 0.140 |
Why?
|
| Radiosurgery | 1 | 2022 | 352 | 0.140 |
Why?
|
| Papillomavirus Infections | 2 | 2018 | 311 | 0.140 |
Why?
|
| Cetuximab | 1 | 2018 | 119 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 110 | 0.140 |
Why?
|
| Computer Simulation | 4 | 2014 | 1147 | 0.130 |
Why?
|
| Patient Participation | 1 | 2020 | 250 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2012 | 463 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 169 | 0.130 |
Why?
|
| Prospective Studies | 7 | 2022 | 4815 | 0.130 |
Why?
|
| Life Expectancy | 2 | 2009 | 93 | 0.130 |
Why?
|
| Receptors, Progesterone | 5 | 2012 | 208 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2026 | 325 | 0.120 |
Why?
|
| DNA Methylation | 5 | 2025 | 734 | 0.120 |
Why?
|
| Genes, BRCA2 | 2 | 2008 | 162 | 0.120 |
Why?
|
| Socioeconomic Factors | 4 | 2010 | 666 | 0.120 |
Why?
|
| SEER Program | 3 | 2019 | 247 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 822 | 0.120 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 547 | 0.120 |
Why?
|
| Internal-External Control | 1 | 2016 | 47 | 0.120 |
Why?
|
| Coronary Disease | 1 | 1997 | 227 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2020 | 450 | 0.110 |
Why?
|
| Religion | 1 | 2016 | 101 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 341 | 0.110 |
Why?
|
| Nomograms | 2 | 2012 | 34 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 337 | 0.110 |
Why?
|
| Mammography | 4 | 2013 | 504 | 0.110 |
Why?
|
| Probability | 1 | 2016 | 356 | 0.110 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 23 | 0.110 |
Why?
|
| Health Literacy | 1 | 2016 | 92 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 913 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2014 | 577 | 0.100 |
Why?
|
| Registries | 3 | 2024 | 1127 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 281 | 0.100 |
Why?
|
| ErbB Receptors | 3 | 2012 | 516 | 0.100 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 52 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 228 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2022 | 3217 | 0.100 |
Why?
|
| alpha-Tocopherol | 1 | 2013 | 9 | 0.100 |
Why?
|
| Selenomethionine | 1 | 2013 | 11 | 0.100 |
Why?
|
| Cyclophosphamide | 4 | 2012 | 284 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1177 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2024 | 11031 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 71 | 0.090 |
Why?
|
| Age Factors | 5 | 2020 | 1972 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 98 | 0.090 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 15 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 554 | 0.090 |
Why?
|
| Arsenic Poisoning | 1 | 2013 | 104 | 0.090 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2012 | 24 | 0.090 |
Why?
|
| Drug Design | 1 | 2012 | 135 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 2569 | 0.090 |
Why?
|
| Body Weight | 3 | 2013 | 456 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 236 | 0.090 |
Why?
|
| Bias | 3 | 2025 | 140 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1784 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 602 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2012 | 285 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 1098 | 0.080 |
Why?
|
| Comorbidity | 2 | 2024 | 1033 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 3 | 2008 | 583 | 0.080 |
Why?
|
| Decision Making | 3 | 2016 | 689 | 0.080 |
Why?
|
| Stroke | 1 | 2000 | 1167 | 0.080 |
Why?
|
| Chemoradiotherapy | 3 | 2018 | 338 | 0.080 |
Why?
|
| Death Certificates | 1 | 2009 | 11 | 0.080 |
Why?
|
| Genes, erbB-2 | 1 | 2009 | 25 | 0.080 |
Why?
|
| Pneumonectomy | 1 | 2012 | 222 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1213 | 0.070 |
Why?
|
| Quinazolines | 1 | 2010 | 221 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 567 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 478 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 219 | 0.070 |
Why?
|
| Time | 1 | 2008 | 80 | 0.070 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 402 | 0.070 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 1 | 2007 | 6 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2008 | 97 | 0.070 |
Why?
|
| Fallopian Tubes | 1 | 2008 | 49 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 638 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2012 | 889 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2012 | 526 | 0.060 |
Why?
|
| Prevalence | 2 | 2024 | 1391 | 0.060 |
Why?
|
| Mutation | 3 | 2008 | 4408 | 0.060 |
Why?
|
| Colorectal Neoplasms | 2 | 2006 | 1107 | 0.060 |
Why?
|
| Disclosure | 1 | 2007 | 98 | 0.060 |
Why?
|
| Parent-Child Relations | 1 | 2007 | 89 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2007 | 188 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 159 | 0.060 |
Why?
|
| Survival | 1 | 2006 | 22 | 0.060 |
Why?
|
| Flutamide | 2 | 2017 | 3 | 0.060 |
Why?
|
| Goserelin | 2 | 2017 | 5 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2007 | 185 | 0.060 |
Why?
|
| Vulnerable Populations | 1 | 2007 | 95 | 0.060 |
Why?
|
| Aneuploidy | 1 | 2005 | 60 | 0.060 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2025 | 16 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 110 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 193 | 0.060 |
Why?
|
| Proton Therapy | 2 | 2016 | 44 | 0.060 |
Why?
|
| North America | 1 | 2005 | 210 | 0.060 |
Why?
|
| Control Groups | 1 | 2025 | 16 | 0.060 |
Why?
|
| Ipilimumab | 1 | 2025 | 69 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2014 | 420 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 41 | 0.050 |
Why?
|
| Brachytherapy | 1 | 2025 | 139 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 34 | 0.050 |
Why?
|
| Technology, Radiologic | 2 | 2016 | 105 | 0.050 |
Why?
|
| Logistic Models | 2 | 2020 | 1275 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 301 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 38 | 0.050 |
Why?
|
| Body Composition | 1 | 2003 | 88 | 0.050 |
Why?
|
| Travel | 1 | 2003 | 77 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2004 | 122 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2004 | 159 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 140 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2011 | 1717 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2004 | 264 | 0.050 |
Why?
|
| Lomustine | 2 | 2012 | 24 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 263 | 0.050 |
Why?
|
| Chicago | 2 | 2024 | 1519 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2004 | 198 | 0.050 |
Why?
|
| Consensus | 1 | 2004 | 308 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2012 | 75 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2014 | 255 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2004 | 479 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 770 | 0.040 |
Why?
|
| Young Adult | 2 | 2012 | 7556 | 0.040 |
Why?
|
| Hematuria | 1 | 2022 | 52 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2004 | 509 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2004 | 447 | 0.040 |
Why?
|
| Carcinoma in Situ | 2 | 1999 | 55 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1142 | 0.040 |
Why?
|
| Computational Biology | 1 | 2024 | 615 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 709 | 0.040 |
Why?
|
| Selection Bias | 1 | 2020 | 38 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 1009 | 0.040 |
Why?
|
| Monte Carlo Method | 2 | 2014 | 194 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2025 | 501 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 194 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2020 | 77 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1097 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 359 | 0.040 |
Why?
|
| Prostate | 1 | 2023 | 434 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 721 | 0.040 |
Why?
|
| Contrast Media | 1 | 2004 | 1013 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 50 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 3030 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2019 | 88 | 0.030 |
Why?
|
| Mastectomy | 3 | 2012 | 272 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 978 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 2673 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2012 | 3627 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 484 | 0.030 |
Why?
|
| China | 1 | 2019 | 277 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1261 | 0.030 |
Why?
|
| Fluorouracil | 3 | 2011 | 543 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 203 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 42 | 0.030 |
Why?
|
| Informed Consent | 1 | 2020 | 281 | 0.030 |
Why?
|
| Re-Irradiation | 1 | 2017 | 18 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.030 |
Why?
|
| Gynecomastia | 1 | 2017 | 8 | 0.030 |
Why?
|
| Canada | 2 | 2011 | 210 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 81 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 155 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 85 | 0.030 |
Why?
|
| Leucovorin | 2 | 2011 | 205 | 0.030 |
Why?
|
| Income | 1 | 2016 | 101 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 345 | 0.030 |
Why?
|
| Leuprolide | 1 | 2014 | 34 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2016 | 160 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 902 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 249 | 0.030 |
Why?
|
| Information Dissemination | 1 | 1995 | 133 | 0.030 |
Why?
|
| Markov Chains | 1 | 2014 | 147 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 168 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 246 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1997 | 396 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 1998 | 686 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2013 | 24 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1995 | 292 | 0.020 |
Why?
|
| Cytostatic Agents | 1 | 2012 | 4 | 0.020 |
Why?
|
| Postmenopause | 1 | 2013 | 109 | 0.020 |
Why?
|
| Cytotoxins | 1 | 2012 | 18 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2012 | 76 | 0.020 |
Why?
|
| Glutamates | 1 | 2012 | 84 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2012 | 43 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 129 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2012 | 88 | 0.020 |
Why?
|
| Credentialing | 1 | 2012 | 15 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2012 | 38 | 0.020 |
Why?
|
| Taxoids | 1 | 2012 | 127 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 3611 | 0.020 |
Why?
|
| Bangladesh | 1 | 2013 | 361 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 191 | 0.020 |
Why?
|
| Guanine | 1 | 2012 | 194 | 0.020 |
Why?
|
| Levamisole | 1 | 2011 | 6 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2005 | 525 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 291 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 1944 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 102 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2012 | 218 | 0.020 |
Why?
|
| Vincristine | 1 | 2011 | 102 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2012 | 179 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2011 | 21 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 246 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 135 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 363 | 0.020 |
Why?
|
| DNA Damage | 1 | 2012 | 399 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 324 | 0.020 |
Why?
|
| Glioma | 1 | 2012 | 309 | 0.020 |
Why?
|
| Senegal | 1 | 2009 | 4 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 267 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 481 | 0.020 |
Why?
|
| Nigeria | 1 | 2009 | 174 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 254 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2005 | 2068 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2005 | 2894 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 473 | 0.020 |
Why?
|
| Genetic Carrier Screening | 1 | 2008 | 58 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2789 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 102 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 1395 | 0.020 |
Why?
|
| CpG Islands | 1 | 2007 | 177 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1816 | 0.020 |
Why?
|
| Methotrexate | 2 | 1997 | 228 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 663 | 0.010 |
Why?
|
| Pedigree | 1 | 2008 | 983 | 0.010 |
Why?
|
| Data Collection | 1 | 2007 | 375 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 214 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 889 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 53 | 0.010 |
Why?
|
| Models, Econometric | 1 | 2005 | 15 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2575 | 0.010 |
Why?
|
| Value of Life | 1 | 2005 | 23 | 0.010 |
Why?
|
| Adolescent | 2 | 2009 | 10127 | 0.010 |
Why?
|
| Stochastic Processes | 1 | 2005 | 77 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2005 | 216 | 0.010 |
Why?
|
| Azacitidine | 1 | 2005 | 152 | 0.010 |
Why?
|
| Minority Groups | 1 | 2006 | 158 | 0.010 |
Why?
|
| ROC Curve | 1 | 2007 | 793 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 160 | 0.010 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2004 | 18 | 0.010 |
Why?
|
| BRCA1 Protein | 1 | 2005 | 222 | 0.010 |
Why?
|
| Interleukin-18 | 1 | 2004 | 27 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2004 | 31 | 0.010 |
Why?
|
| Receptors, Interferon | 1 | 2004 | 33 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 599 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 970 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 60 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 461 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 2002 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 110 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2004 | 178 | 0.010 |
Why?
|
| Pyrroles | 1 | 2004 | 166 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 239 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2003 | 192 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 286 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2006 | 394 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 369 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 304 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 690 | 0.010 |
Why?
|
| Indoles | 1 | 2004 | 334 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 883 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 830 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 297 | 0.010 |
Why?
|
| Cognition | 1 | 2007 | 669 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 1321 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 828 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 1261 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2001 | 86 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 2054 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 523 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1161 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 418 | 0.010 |
Why?
|
| Melanoma | 1 | 2004 | 524 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1230 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 727 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 1891 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 28950 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 219 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 2209 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 1999 | 84 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 206 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 826 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 2653 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 1333 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 3612 | 0.010 |
Why?
|
| Federal Government | 1 | 1995 | 28 | 0.010 |
Why?
|
| Child | 1 | 2007 | 7730 | 0.010 |
Why?
|
| Government Regulation | 1 | 1995 | 49 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 1996 | 242 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 12718 | 0.000 |
Why?
|